Quotient Sciences, a leading integrated CRDMO (Contract Research, Development and Manufacturing Organization), is pleased to announce an extended commercial supply partnership with Ipsen, a global ...

YOU’RE WATCHING. WLKY NEWS. A HOLIDAY TRADITION BROUGHT SMILES TO YOUNG PATIENTS AT NORTON CHILDREN’S HOSPITAL. THE FOP MADE SURE KIDS DON’T MISS OUT ON THE JOY OF THE SEASON. JOYCE OGIRRI SHOWS US ...

FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective ...

PARIS, FRANCE, 19 December 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the pivotal Phase II FALKON trial did not meet its primary endpoint of reducing new heterotopic ossification ...

BRISBANE, Calif.--(BUSINESS WIRE)--āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of severe bone and connective tissue disorders, today ...

Advisory committee voted 10 for and 4 against that evidence from the Phase III MOVE study show palovarotene is an effective treatment in patients with the ultra-rare bone disease fibrodysplasia ...

Garetosmab is a fully-human monoclonal antibody designed to bind and neutralize Activin A, a major promoter of heterotopic ossification in patients with FOP.

A Colorado family is calling for change and sharing their struggle after a clinical trial their son relied on suddenly ended.

Imagine a bruise that never heals — instead, it hardens into bone. A small swelling that doesn’t fade but permanently locks a ...

The companies have extended a commercial supply partnership for the manufacture of Sohonos (palovarotene), which is a ...